Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amylyx Pharmaceuticals (AMLX) Current Assets: 2021-2024

Historic Current Assets for Amylyx Pharmaceuticals (AMLX) over the last 4 years, with Dec 2024 value amounting to $189.4 million.

  • Amylyx Pharmaceuticals' Current Assets rose 44.08% to $353.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $353.4 million, marking a year-over-year increase of 44.08%. This contributed to the annual value of $189.4 million for FY2024, which is 59.23% down from last year.
  • Amylyx Pharmaceuticals' Current Assets amounted to $189.4 million in FY2024, which was down 59.23% from $464.7 million recorded in FY2023.
  • In the past 5 years, Amylyx Pharmaceuticals' Current Assets registered a high of $464.7 million during FY2023, and its lowest value of $105.0 million during FY2021.
  • Moreover, its 3-year median value for Current Assets was $382.1 million (2022), whereas its average is $345.4 million.
  • Its Current Assets has fluctuated over the past 5 years, first soared by 264.11% in 2022, then plummeted by 59.23% in 2024.
  • Yearly analysis of 4 years shows Amylyx Pharmaceuticals' Current Assets stood at $105.0 million in 2021, then surged by 264.11% to $382.1 million in 2022, then increased by 21.60% to $464.7 million in 2023, then slumped by 59.23% to $189.4 million in 2024.